Advertisement

Clinical PET pp 347-356 | Cite as

Urologic Cancer

  • Tomio Inoue
  • Nobukazu Takahashi
  • Tetsuya Higuchi

Abstract

Positron emission tomography (PET) is a unique imaging modality with the capability of studying regional metabolism. 18F-fluorodeoxyglucose (FDG) is the most widely used tracer in the field of PET oncology. The clinical utility of oncology PET using FDG has been proven in the staging and restaging of malignant tumors such as head/neck, lung, breast, and colorectal cancers, as well as malignant lymphoma, and melanoma. In the field of urology, FDG-PET has been evaluated in the relevant malignancies with promising results in certain areas and disappointing results in others. At this stage FDG-PET is capable of visualizing urologic tumors and associated lymph nodes and distal metastatic sites. However, its use is severely limited by the excretion of the most commonly used radioisotope via the urinary tract, making pelvic imaging particularly unrewarding. 11C-choline upregulated in malignant cells has shown potential usefulness in brain, prostate, and esophageal cancers with enhanced synthesis of membrane phospholipids. This chapter discusses the clinical usefulness of oncology PET in the field of urology including renal cell, urinary bladder, and prostate cancer, as well as testicular tumors. We review the related articles of PET oncology in the field of urology.

Keywords

Positron Emission Tomography Renal Cell Carcinoma Pelvic Lymph Node Axial Compute Tomography Urinary Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825–830.PubMedCrossRefGoogle Scholar
  2. 2.
    Safei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57: 56–62.Google Scholar
  3. 3.
    Poggi MM, Patronas N, Buttman JA, et al. Intramedullary spinal cord metastasis from renal cell carcinoma: detection by positron emission tomography. Clin Nucl Med 2001; 26: 837–839.PubMedCrossRefGoogle Scholar
  4. 4.
    See WA, Fuller JR. Staging of advanced bladder cancer. Current concepts and pitfalls. Urol Clin North Am 1992; 19: 663–683.PubMedGoogle Scholar
  5. 5.
    Ahlstrom H, Malmstrom PU, Letocha H, et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996; 37: 180–185.PubMedGoogle Scholar
  6. 6.
    Heicappell R, Muller-Mattheis V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 1999; 36: 58 2587.Google Scholar
  7. 7.
    Hara T, Kosaka M, Kishi H. PET imaging of brain tumor with [methyl-11C] choline. J Nucl Med 1997; 38: 842–847.PubMedGoogle Scholar
  8. 8.
    Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon11-choline. J Nucl Med 1998; 39: 990–995.PubMedGoogle Scholar
  9. 9.
    Inoue T, Oriuchi N, Tomiyoshi K, et al. A shifting landscape: What will be next FDG in PET oncology? Ann Nucl Med 2002; 16: 1–9.PubMedCrossRefGoogle Scholar
  10. 10.
    DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of F18 labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42: 1805–1814.PubMedGoogle Scholar
  11. 11.
    Kosuda S, Fisher S, Kison PV, et al. Uptake of 2-deoxy-2418F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med 1997; 11: 195–199.PubMedCrossRefGoogle Scholar
  12. 12.
    Spermon JR, De Geus-Oei LF, Kiemeney LA, et al. The role of (18)fluoro2-deoxyglucose positron emission tomography in initial staging and restaging after chemotherapy for testicular germ cell tumours. Br J Urol Int 2002; 89: 549–556.CrossRefGoogle Scholar
  13. 13.
    De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2–18-fluoro-2-deoxy-D-glucose positron emission tomography for residual post-chemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740–3744.PubMedGoogle Scholar
  14. 14.
    Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of F-18 FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Ira 2002; 68: 157–163.CrossRefGoogle Scholar
  15. 15.
    Cremerious U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998; 39: 815–822.Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Tomio Inoue
  • Nobukazu Takahashi
  • Tetsuya Higuchi

There are no affiliations available

Personalised recommendations